The ultimate goal of precision medicine is a unique drug for each patient. However, this N-of-1 model directly conflicts with the current economic and regulatory system, which incentivizes developing drugs for large populations to recoup massive R&D and approval costs.

For personalized cancer vaccines, the speed of development from biopsy to injection is critical. Traditional methods are too slow. mRNA technology enables custom vaccine creation in just weeks, making a rapid, tailored response to a patient's specific tumor possible for the first time.

For gene editing to achieve its potential, companies must solve an economic problem, not just a scientific one. The key is developing a manufacturing system that dramatically lowers costs, making one-time cures for the "long tail" of rare mutations financially viable and accessible.

Beyond clinical efficacy, patient experience is a key differentiator. Patients strongly prefer single-administration ("one and done") gene therapies over treatments requiring regular injections. This is due to the cumulative stress, cost, and logistical burden of lifelong, recurring treatments, which directly informs therapeutic modality choice.

Despite promising data from leaders like Moderna, many cancer vaccine companies struggle to raise capital. This is driven by a perception that big pharma is largely uninterested in the modality, preferring to invest in and acquire assets in hotter areas like ADCs and in-vivo CAR therapies.

Unlike a drug that can be synthesized to a chemical standard, most vaccines are living biological products. This means the entire manufacturing process must be perfectly managed and cannot be altered without re-validation. This biological complexity makes production far more difficult and expensive than typical pharmaceuticals.

The standard approach to reducing cancer drug toxicity is narrowing the target to specific mutations (e.g., HER2, KRAS). While this improves safety, it drastically shrinks the addressable patient population for each new therapy. This puts immense pressure on the pharmaceutical business model, where development costs average $2.5 billion per drug.

While Moderna's Phase 3 success is a scientific breakthrough, its real-world application is uncertain. The personalized nature creates a significant manufacturing burden and high cost, raising questions about whether payers will reimburse an expensive therapy used to delay, not cure, cancer in a broad adjuvant setting.

While mRNA vaccines were a triumph, mRNA therapeutics have never been approved. Therapeutics require higher protein production and precise cellular targeting, a far greater technical challenge than the broad immune response stimulated by vaccines. This distinction is a major blind spot for the public.